X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (219232) 219232
Publication (24841) 24841
Book Review (2926) 2926
Book / eBook (2829) 2829
Book Chapter (545) 545
Conference Proceeding (391) 391
Dissertation (230) 230
Magazine Article (206) 206
Data Set (46) 46
Government Document (40) 40
Paper (23) 23
Web Resource (18) 18
Trade Publication Article (13) 13
Streaming Video (7) 7
Presentation (3) 3
Newspaper Article (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (187501) 187501
index medicus (118882) 118882
animals (84186) 84186
oncology (84099) 84099
female (73780) 73780
cell line, tumor (65126) 65126
cancer (64328) 64328
male (50851) 50851
mice (50722) 50722
apoptosis (43290) 43290
expression (34949) 34949
apoptosis - drug effects (32199) 32199
antineoplastic agents - pharmacology (30446) 30446
research (30065) 30065
middle aged (28988) 28988
tumors (27645) 27645
cell proliferation - drug effects (25146) 25146
cell biology (25025) 25025
biochemistry & molecular biology (24551) 24551
proteins (24491) 24491
chemotherapy (24481) 24481
aged (23589) 23589
tumor cells, cultured (22702) 22702
care and treatment (21599) 21599
metastasis (21494) 21494
adult (21488) 21488
gene expression (21431) 21431
breast cancer (20969) 20969
health aspects (20162) 20162
antineoplastic agents - therapeutic use (19043) 19043
genetic aspects (18505) 18505
pharmacology & pharmacy (18265) 18265
signal transduction (17917) 17917
research article (17784) 17784
signal transduction - drug effects (17644) 17644
article (17416) 17416
neoplasms - drug therapy (16876) 16876
medicine (16436) 16436
mice, nude (16202) 16202
analysis (15889) 15889
activation (15888) 15888
growth (15284) 15284
gene expression regulation, neoplastic (15122) 15122
gene expression regulation, neoplastic - drug effects (14856) 14856
mutation (14321) 14321
cancer therapies (14310) 14310
dose-response relationship, drug (14294) 14294
cells (14234) 14234
cell survival - drug effects (14183) 14183
kinases (14097) 14097
phosphorylation (14019) 14019
multidisciplinary sciences (14012) 14012
breast neoplasms - pathology (13952) 13952
prognosis (13931) 13931
therapy (13515) 13515
cell proliferation (13459) 13459
xenograft model antitumor assays (13314) 13314
breast-cancer (13116) 13116
cell cycle (12356) 12356
carcinoma (12255) 12255
development and progression (12229) 12229
in-vitro (12223) 12223
rats (12207) 12207
inhibition (12133) 12133
neoplasms. tumors. oncology. including cancer and carcinogens (12066) 12066
blotting, western (12056) 12056
medicine, research & experimental (11956) 11956
physiological aspects (11725) 11725
treatment outcome (11638) 11638
breast neoplasms - drug therapy (11619) 11619
drug resistance, neoplasm (11535) 11535
breast neoplasms - metabolism (11309) 11309
biology (10872) 10872
neoplasms (10829) 10829
survival (10537) 10537
immunohistochemistry (10535) 10535
science (10454) 10454
proliferation (10231) 10231
in-vivo (10135) 10135
neoplasms - metabolism (10103) 10103
neoplasms - pathology (10049) 10049
transfection (9946) 9946
mice, inbred balb c (9833) 9833
cell division - drug effects (9747) 9747
studies (9725) 9725
gene-expression (9613) 9613
angiogenesis (9542) 9542
cell line (9430) 9430
lung cancer (9256) 9256
down-regulation (9225) 9225
drug therapy (9178) 9178
protein (9036) 9036
lung neoplasms - drug therapy (9008) 9008
risk factors (8926) 8926
cell growth (8828) 8828
medical prognosis (8715) 8715
colorectal cancer (8697) 8697
lung neoplasms - pathology (8633) 8633
flow cytometry (8593) 8593
genes (8586) 8586
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (2047) 2047
Collection Dvlpm't (Acquisitions) - Closed Orders (114) 114
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (104) 104
Collection Dvlpm't (Acquisitions) - Vendor file (103) 103
Online Resources - Online (48) 48
UTL at Downsview - May be requested (41) 41
UofT at Mississauga - Stacks (32) 32
Scarborough Hospital - General (20) 20
Lakeridge Health Sciences - Oshawa (14) 14
St. Michael's Hospital - Stacks (14) 14
Scarborough Hospital - Birchmount (13) 13
Humber River Regional Hospital - Finch Stacks (12) 12
Dentistry (Harry R Abbott) - Stacks (11) 11
Gerstein Science - Circulation Desk (11) 11
Markham Stouffville Hospital - Stacks (11) 11
Credit Valley Hospital - Stacks (10) 10
Humber River Regional Hospital - Church Stacks (10) 10
New College (Ivey) - Stacks (10) 10
UofT at Scarborough - Stacks (10) 10
Providence Healthcare - Stacks (9) 9
Mt Sinai Hospital - Pathology (8) 8
Robarts - Stacks (8) 8
St. Michael's College (John M. Kelly) - 2nd Floor (8) 8
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (7) 7
OISE - Stacks (7) 7
Providence Healthcare - Reference (6) 6
Dentistry (Harry R Abbott) - Withdrawn (5) 5
Women's College Hospital - Stacks (5) 5
Chemistry (A D Allen) - Stacks (4) 4
Gerstein Science - Reference (4) 4
Toronto East General Hospital - Stacks (4) 4
Credit Valley Hospital - Special Collections (3) 3
Earth Sciences (Noranda) - Stacks (3) 3
Gerstein Science - Not Returned (3) 3
St Josephs Health Centre - Stacks (3) 3
St. Michael's Hospital - Circulation Desk (3) 3
Trinity College (John W Graham) - Stacks (3) 3
UofT Schools - Stacks (3) 3
Victoria University E.J. Pratt - Stacks (3) 3
West Park Healthcare Centre - Stacks (3) 3
Credit Valley Hospital - Reference (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Law (Bora Laskin) - Stacks (2) 2
Regis College - Stacks (2) 2
Scarborough Hospital - Hospital Department (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Reference (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Toronto East General Hospital - Online (2) 2
Trillium Health Centre - Stacks (2) 2
Victoria University E.J. Pratt - Oversize (2) 2
Victoria University Emmanuel College - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Credit Valley Hospital - Reserve desk (1) 1
Dentistry (Harry R Abbott) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Oversize (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Faculty of Information - Subject Analysis Systems (1) 1
Gerstein Science - Processing (1) 1
Gerstein Science - Reserve desk (1) 1
Gerstein Science - Withdrawn (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Lakeridge Health Sciences - Stacks (1) 1
Markham Stouffville Hospital - Storage (1) 1
Mathematical Sciences - Stacks (1) 1
OISE - May be requested in 6-10 wks (1) 1
OISE - Missing (1) 1
Pharmacy (1) 1
Physics - Course Reserves (1) 1
Providence Healthcare - Withdrawn (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
St. Michael's College (John M. Kelly) - Circulation Desk (1) 1
Sunnybrook Health Sciences Centre - Holland Reference (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Stacks (1) 1
Toronto East General Hospital - Missing (1) 1
Trinity College (John W Graham) - Wycliffe Storage (1) 1
UofT at Mississauga - Circulation Desk (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Withdrawn (1) 1
Victoria University E.J. Pratt - Circulation Desk (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (217920) 217920
Chinese (2345) 2345
Japanese (570) 570
German (484) 484
French (455) 455
Russian (380) 380
Spanish (153) 153
Portuguese (112) 112
Polish (87) 87
Italian (71) 71
Hungarian (70) 70
Korean (29) 29
Czech (24) 24
Ukrainian (21) 21
Dutch (19) 19
Swedish (18) 18
Norwegian (14) 14
Turkish (10) 10
Arabic (9) 9
Romanian (7) 7
Danish (6) 6
Bulgarian (5) 5
Serbian (5) 5
Croatian (4) 4
Hebrew (4) 4
Finnish (3) 3
Persian (3) 3
Slovenian (2) 2
Afrikaans (1) 1
Amharic (1) 1
Kurdish (1) 1
Lithuanian (1) 1
Manx (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Cancer, ISSN 0007-0920, 01/2016, Volume 114, Issue 2, pp. 177 - 187
Background: Oestrogen receptor-negative (ER-) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and... 
CELLS | REDUCES TUMOR-GROWTH | STAT1 | DNA-DAMAGE | chemotherapy | IFN | THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | ER-negative breast cancer | GENE-EXPRESSION | RESISTANCE | PATHWAY ANALYSIS | predictive signature | XENOGRAFTS | Caspase 7 - metabolism | Immunohistochemistry | Receptors, Estrogen - metabolism | Cytoskeletal Proteins - genetics | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Caspase 3 - metabolism | Gene Expression Profiling | Intracellular Signaling Peptides and Proteins - metabolism | Interferon-gamma - metabolism | Carrier Proteins - drug effects | Mitochondrial Proteins - drug effects | STAT1 Transcription Factor - metabolism | Mitochondrial Proteins - metabolism | Caspase 3 - genetics | Interferon-beta - genetics | Cytokines - genetics | Intracellular Signaling Peptides and Proteins - genetics | Real-Time Polymerase Chain Reaction | Ubiquitins - metabolism | Caspase 7 - drug effects | Antigens - drug effects | Caspase 7 - genetics | Membrane Proteins - genetics | Myxovirus Resistance Proteins - drug effects | Capecitabine - pharmacology | STAT1 Transcription Factor - genetics | Breast Neoplasms - drug therapy | Blotting, Western | Breast Neoplasms - genetics | Interferon-beta - metabolism | Signal Transduction - drug effects | Mice, Nude | Membrane Proteins - drug effects | Mice | Myxovirus Resistance Proteins - genetics | Ubiquitins - drug effects | Antigens - genetics | Neoplasm Transplantation | Phosphorylation | Ubiquitins - genetics | Gene Expression Regulation, Neoplastic | Interferon-gamma - drug effects | STAT1 Transcription Factor - drug effects | Mitochondrial Proteins - genetics | Interferon-beta - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | In Situ Hybridization | Caspase 3 - drug effects | Cytoskeletal Proteins - metabolism | Female | Cytoskeletal Proteins - drug effects | Membrane Proteins - metabolism | Interferon-gamma - genetics | Cytokines - metabolism | Antigens - metabolism | Cisplatin - pharmacology | Xenograft Model Antitumor Assays | Carrier Proteins - genetics | Animals | Carrier Proteins - metabolism | Cytokines - drug effects | Myxovirus Resistance Proteins - metabolism | Translational Therapeutics
Journal Article
Nature Medicine, ISSN 1078-8956, 09/2017, Volume 23, Issue 9, pp. 1055 - 1062
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising anticancer therapies. The gene encoding the E3 ubiquitin ligase... 
SELECTIVE-INHIBITION | TARGET | MEDICINE, RESEARCH & EXPERIMENTAL | ANDROGEN RECEPTOR | STEM-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACUTE MYELOID-LEUKEMIA | ENHANCERS | CELL BIOLOGY | RNA-SEQ | BROMODOMAIN INHIBITION | MUTATIONS | BRD4 | Prostatic Neoplasms - metabolism | Immunoprecipitation | TOR Serine-Threonine Kinases - metabolism | Humans | Drug Resistance, Neoplasm | Male | Gene Expression Profiling | Molecular Targeted Therapy | Mechanistic Target of Rapamycin Complex 1 | Transcription Factors - drug effects | Multiprotein Complexes - metabolism | Prostatic Neoplasms - genetics | Proteasome Endopeptidase Complex - drug effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Nuclear Proteins - drug effects | Nuclear Proteins - genetics | Proto-Oncogene Proteins c-akt - metabolism | TOR Serine-Threonine Kinases - drug effects | Multiprotein Complexes - drug effects | Prostatic Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - metabolism | Repressor Proteins - metabolism | RNA-Binding Proteins - antagonists & inhibitors | Triazoles - therapeutic use | Cell Survival | Repressor Proteins - genetics | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Azepines - therapeutic use | RNA-Binding Proteins - drug effects | Azepines - pharmacology | Transcription Factors - metabolism | Triazoles - pharmacology | Nuclear Proteins - antagonists & inhibitors | Protein-Serine-Threonine Kinases - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | RNA-Binding Proteins - metabolism | rac1 GTP-Binding Protein - metabolism | Proto-Oncogene Proteins c-akt - drug effects | rac1 GTP-Binding Protein - genetics | Gene mutations | Physiological aspects | Genetic aspects | Research | Drug resistance | Drug therapy | Prostate cancer | Ubiquitin | Inhibitor drugs | Stabilization | AKT protein | Activation | Biosynthesis | Degradation | Proteins | Ubiquitination | Transcription activation | Bioindicators | Ubiquitin-protein ligase | Binding | Rac1 protein | Tumor cell lines | Gene expression | Cholesterol | Mutants | Inhibitors | Proteasomes | Biomarkers | Bet protein | Prostate | Cancer | Guanosinetriphosphatase
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2009, Volume 100, Issue 9, pp. 1425 - 1433
Curcumin has been shown to inhibit the growth of various types of cancer cells; however, at concentrations much above the clinically achievable levels in... 
Curcumin | Chk1 | G2/M arrest | DNA damage | Pancreatic cancer | CARCINOMA-CELLS | DNA-DAMAGE | DOWN-REGULATION | REGULATED GENE-PRODUCTS | FACTOR-KAPPA-B | BENZYL ISOTHIOCYANATE | I CLINICAL-TRIAL | pancreatic cancer | ONCOLOGY | PROSTATE-CANCER | CHEMOPREVENTIVE AGENT | curcumin | Cell Cycle Proteins - drug effects | Protein Kinases - metabolism | Gene Expression Regulation, Enzymologic - drug effects | Protein Kinases - genetics | Gene Silencing - drug effects | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Collagen Type XI - metabolism | DNA-Binding Proteins - metabolism | Pancreatic Neoplasms - drug therapy | Transfection | Tumor Suppressor Proteins - genetics | Caspase 3 - drug effects | Cell Cycle Proteins - genetics | Gene Expression Regulation, Neoplastic - drug effects | Protein-Serine-Threonine Kinases - metabolism | DNA Damage - drug effects | Protein Kinases - drug effects | Tumor Suppressor Proteins - metabolism | Collagen Type XI - drug effects | Pancreatic Neoplasms - pathology | Cell Cycle Proteins - metabolism | Curcumin - pharmacology | DNA-Binding Proteins - drug effects | Pancreatic Neoplasms - enzymology | Protein-Serine-Threonine Kinases - genetics | Ataxia Telangiectasia Mutated Proteins | DNA-Binding Proteins - genetics | Cell Division - drug effects | Protein-Serine-Threonine Kinases - drug effects | Cell Line, Tumor | Checkpoint Kinase 1 | Tumor Suppressor Proteins - drug effects | Cell Cycle - drug effects | Translational Therapeutics | M arrest
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 10/2013, Volume 188, Issue 7, pp. 770 - 775
The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR... 
Molecular targeted therapy | Lung cancer | Cancer genomics | RET | GEFITINIB | EML4-ALK FUSION GENE | KINASE INHIBITOR | ALK INHIBITOR | SOMATIC MUTATIONS | EGFR | CHEMOTHERAPY | lung cancer | PHASE-II TRIAL | RESPIRATORY SYSTEM | CRIZOTINIB | cancer genomics | molecular targeted therapy | CRITICAL CARE MEDICINE | Lung Neoplasms - drug therapy | Oncogene Proteins - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma of Lung | Receptor, ErbB-2 - genetics | Genomics | Humans | ErbB Receptors - genetics | Antineoplastic Agents - therapeutic use | ErbB Receptors - therapeutic use | Anaplastic Lymphoma Kinase | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adenocarcinoma - genetics | ras Proteins - drug effects | Receptor, ErbB-2 - drug effects | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Proto-Oncogene Proteins - drug effects | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - drug effects | Proto-Oncogene Proteins - genetics | Mutation - genetics | Adenocarcinoma - drug therapy | Oncogene Proteins - drug effects | Proto-Oncogene Proteins c-met - genetics | Mutation - drug effects | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Receptor Protein-Tyrosine Kinases - therapeutic use | Proto-Oncogene Proteins c-ret - drug effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Proto-Oncogene Proteins c-ret - genetics | Pulmonary
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 750 - 759
Abstract The hedgehog (Hh) pathway is aberrantly activated in a number of tumors. In medulloblastoma, basal cell carcinoma, and rhabdomyosarcoma, mutations in... 
Hematology, Oncology and Palliative Medicine | Hedgehog | Smoothened | Combination chemotherapy | Targeted therapy | Novel antitumor agents | Cell signaling | STEM-CELLS | ACTIVATED PROTEIN-KINASE | SELF-RENEWAL | CHRONIC MYELOID-LEUKEMIA | EPITHELIAL-MESENCHYMAL TRANSITION | GLI TRANSCRIPTION FACTORS | ONCOLOGY | BASAL-CELL CARCINOMA | PROSTATE-CANCER | TARGETING HEDGEHOG | SONIC-HEDGEHOG | Hedgehog Proteins - drug effects | Neoplasms - metabolism | TOR Serine-Threonine Kinases - metabolism | Receptors, Notch - metabolism | Humans | Hedgehog Proteins - metabolism | Receptor, Epidermal Growth Factor - drug effects | Phosphatidylinositol 3-Kinases - metabolism | raf Kinases - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptor, Epidermal Growth Factor - metabolism | Phosphatidylinositol 3-Kinases - drug effects | Proto-Oncogene Proteins c-akt - metabolism | TOR Serine-Threonine Kinases - drug effects | Janus Kinase 2 - antagonists & inhibitors | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins p21(ras) - metabolism | Receptors, Notch - drug effects | Fusion Proteins, bcr-abl - drug effects | Neoplasms - drug therapy | Proto-Oncogene Proteins p21(ras) - drug effects | Animals | MAP Kinase Signaling System - drug effects | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | raf Kinases - drug effects | Fusion Proteins, bcr-abl - metabolism | Proto-Oncogene Proteins c-akt - drug effects | Receptor Cross-Talk - drug effects | Care and treatment | Health aspects | Leukemia | Analysis | Cancer
Journal Article
Nature Communications, ISSN 2041-1723, 07/2017, Volume 8, Issue 1, p. 16078
BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anticancer targets. Using small cell lung cancer (SCLC) as a model, we... 
CELL LUNG-CANCER | SELECTIVE-INHIBITION | BAK ACTIVATION | POTENT | MULTIDISCIPLINARY SCIENCES | BIM | TRANSCRIPTION | DEATH | CDK INHIBITOR | ABT-263 | BH3 DOMAIN | Lung Neoplasms - drug therapy | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Apoptosis Regulatory Proteins - drug effects | Myeloid Cell Leukemia Sequence 1 Protein - drug effects | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - metabolism | bcl-X Protein - drug effects | Proto-Oncogene Proteins c-bcl-2 - metabolism | bcl-X Protein - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Aniline Compounds - pharmacology | Cyclin-Dependent Kinase 9 - antagonists & inhibitors | Sulfonamides - pharmacology | Apoptosis Regulatory Proteins - metabolism | Drug Synergism | Pyridinium Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | High-Throughput Screening Assays | Apoptosis Regulatory Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - drug effects | Cell Line, Tumor | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | bcl-X Protein - metabolism | Doxorubicin - pharmacology | Regulators | Bax protein | Bcl-2 protein | Small cell lung carcinoma | Lung cancer | High-throughput screening | Doxorubicin | BAK protein | Mcl-1 protein | Proteins | Mitochondria | Inhibitors | Bcl-x protein | Anthracycline | Addiction | Cell death | Sequestering | Cancer | Apoptosis
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2009, Volume 101, Issue 19, pp. 1308 - 1324
The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the range of treatment options for... 
CELL LUNG-CANCER | PHASE-III TRIAL | TYROSINE KINASE INHIBITORS | COLON-CANCER | KRAS MUTATIONS | K-RAS MUTATIONS | PROGRESSION-FREE-SURVIVAL | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | IN-SITU HYBRIDIZATION | GENE COPY NUMBER | PTEN Phosphohydrolase - drug effects | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Colorectal Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - drug effects | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cetuximab | Odds Ratio | PTEN Phosphohydrolase - genetics | Proto-Oncogene Proteins - drug effects | Antibodies, Monoclonal - pharmacology | Proto-Oncogene Proteins - genetics | Randomized Controlled Trials as Topic | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins p21(ras) - drug effects | Animals | Class I Phosphatidylinositol 3-Kinases | Mutation - drug effects | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - pathology | Neoplasm Staging | Research Design | Usage | Care and treatment | Prognosis | Gene mutations | Colorectal cancer | Monoclonal antibodies | Development and progression | Genetic aspects | Research | Biological markers | Health aspects | Review
Journal Article
Leukemia, ISSN 0887-6924, 07/2011, Volume 25, Issue 7, pp. 1064 - 1079
It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The... 
mTOR | translation | sensitivity | PI3K | therapy | resistance | TUMOR-SUPPRESSOR CANDIDATE | PROTEIN-KINASE | INITIATION-FACTOR 4E | ACUTE MYELOID-LEUKEMIA | GROWTH-FACTOR RECEPTOR | BONE-MARROW MICROENVIRONMENT | ONCOLOGY | AKT/PROTEIN-KINASE-B | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOPOIETIC STEM-CELLS | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Neoplasm Proteins - physiology | PTEN Phosphohydrolase - physiology | Apoptosis - genetics | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | Gene Expression Regulation, Leukemic - genetics | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Transcription Factors - drug effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | PTEN Phosphohydrolase - antagonists & inhibitors | TOR Serine-Threonine Kinases - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | TOR Serine-Threonine Kinases - physiology | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Leukemia - genetics | Multiprotein Complexes - drug effects | PTEN Phosphohydrolase - genetics | Proteins - physiology | Transcription Factors - physiology | RNA, Messenger - genetics | Gene Expression Regulation, Leukemic - drug effects | Leukemia - drug therapy | Transcription Factors - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - physiology | Multiprotein Complexes - physiology | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Pseudogenes | Signal Transduction - drug effects | Phosphatidylinositol 3-Kinases - physiology | Proteins - drug effects | RNA, Neoplasm - genetics | Protein Biosynthesis - drug effects | MicroRNAs - genetics | Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Genes | Leukemia | Physiological aspects | Development and progression | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Health aspects
Journal Article